AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.
US-based vaccine developer Moderna Therapeutics set its pricing range at $22 to $24 yesterday for an initial public offering that will offer exits to pharmaceutical firms Merck & Co, AstraZeneca and Alexion Pharmaceuticals.
The company will issue 21.7 million shares and raise more than $521m if it floats at the top of the range. It will list on the Nasdaq Global Select Market.
Founded in 2010, Moderna is developing vaccines and drugs based on messenger RNA (mRNA), which transfers…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
